<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00240526</url>
  </required_header>
  <id_info>
    <org_study_id>100450</org_study_id>
    <nct_id>NCT00240526</nct_id>
  </id_info>
  <brief_title>LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers</brief_title>
  <official_title>Comparative Study of the Immunogenicity and Protective Efficacy of GlaxoSmithKline Biologicals' Rec-DNA Hepatitis B Vaccine With or Without Hepatitis B Immunoglobulins (HBIg) in Newborns of HBeAg+ Mothers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      To evaluate the persistence of anti-HBs antibodies up to 16, 17, 18, 19 and 20 years after
      administration of the first dose of the study vaccine. The Protocol Posting has been updated
      in order to comply with the FDA Amendment Act, Sep 2007.

      No additional subjects will be recruited during this long-term follow-up study and no vaccine
      will be administered.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary study was to evaluate the reactogenicity, immunogenicity and protective efficacy
      of a hepatitis B vaccine in healthy neonates of HBeAg positive mothers if administered with
      or without a dose of HBIg at birth. The current study describes the long term follow up of
      these subjects between Y16 and 20 after primary vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration as Measured by Enzyme-Linked Immunosorbent Assay (ELISA).</measure>
    <time_frame>At Years 15, 16, 17, 18, 19 and 20</time_frame>
    <description>Concentrations given as GMC expressed as milli-international unit per millilitre (mIU/mL).
Note: At Year 15 and 16, a commercial ELISA was used. From Year 17 to Year 20, anti-HBs antibody concentrations were tested with a validated in-house assay with cut-off 3.3mIU/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration as Measured by ChemiLuminescence ImmunoAssay (CLIA).</measure>
    <time_frame>At Years 19 and 20</time_frame>
    <description>Concentrations given as GMC expressed as milli-international unit per millilitre (mIU/mL).
Note: There was a change of assay kit at Year 19 time-point, thus for the sake of bridging, blood samples corresponding to Year 19 were re-tested with new CLIA. At Year 19 and 20, anti-HBs antibody concentrations tested with the CLIA with cut-off 6.2 mIU/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above Pre-defined Cut-off Values Enzyme-Linked Immunosorbent Assay (ELISA).</measure>
    <time_frame>At Years 15, 16, 17, 18, 19 and 20</time_frame>
    <description>Anti-hepatitis B surface antigen (anti-HBs) antibody cut-off values assessed include 1.0 and 10 mIU/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjusted Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above Pre-defined Cut-off Values as Measured by ChemiLuminescence ImmunoAssay (CLIA)</measure>
    <time_frame>At Years 19 and 20</time_frame>
    <description>Anti-hepatitis B surface antigen (anti-HBs) antibody cut-off values assessed include 1.0 and 10 mIU/mL.
Note: Missing CLIA anti-HBs concentrations, for subjects with ELISA results available, are estimated by multiple imputations and GMCs and number of subjects were adjusted for these imputations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Positive Results for Serological Markers for Hepatitis B Infection</measure>
    <time_frame>At Years 15, 16, 17, 18, 19 and 20</time_frame>
    <description>Serological markers for hepatitis B infection assessed are hepatitis B surface antigen (HBsAg), antibodies to hepatitis B core antigen (anti-HBc), hepatitis B e antigen (HBeAg) and antibodies to hepatitis B e antigen (anti-HBe).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Different Hepatitis B Infection Statuses</measure>
    <time_frame>Over the entire follow up period (Final assessment of clinical significance was analyzed after the Year 20 time point)</time_frame>
    <description>Categories hepatitis B (HB) infection:
Chronic infection: HBsAg and anti-HBc pos (pos) in more than two consecutive samples
False positive: single HB marker (HBsAg, HBeAg, anti-HBc) pos + all other markers negative (neg) in one sample. Consecutive time points all neg.
Possible subclinical breakthrough infection: One or more HB markers pos in one or more consecutive samples.
Isolated natural booster: &gt;4-fold increase of anti-HBs concentrations if &lt;100 mIU/mL at previous sample OR &gt;2- fold increase of anti-HBs concentrations if &gt;=100 mIU/mL at previous sample + other markers neg</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Engerix 4D + HBIg Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Engerix 3D + HBIg Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Engerix 4D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Engerix 3D Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix™ -B</intervention_name>
    <description>3 (Groups A and C) or 4 (Groups B and D) intramuscular injections during the primary study</description>
    <arm_group_label>Engerix 4D</arm_group_label>
    <arm_group_label>Engerix 3D + HBIg Group</arm_group_label>
    <arm_group_label>Engerix 3D Group</arm_group_label>
    <arm_group_label>Engerix 4D + HBIg Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis B immunoglobulin (HBIg)</intervention_name>
    <description>1 intramuscular injections at birth (primary study)</description>
    <arm_group_label>Engerix 3D + HBIg Group</arm_group_label>
    <arm_group_label>Engerix 4D + HBIg Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who had received at least one dose of the study vaccine in the primary study

          -  Written informed consent obtained from each subject before each blood sampling visit

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2005</study_first_submitted>
  <study_first_submitted_qc>October 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2005</study_first_posted>
  <results_first_submitted>June 14, 2010</results_first_submitted>
  <results_first_submitted_qc>June 14, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 15, 2010</results_first_posted>
  <last_update_submitted>October 14, 2016</last_update_submitted>
  <last_update_submitted_qc>October 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B immunoglobulin</keyword>
  <keyword>Hepatitis B antibody persistence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>100450</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>100450</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>100450</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>100450</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>100450</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>100450</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The baseline characteristics are given for the Year 15 time point. Therefore the number of participants in the Engerix-3D Group is 21, as in the Year 15 participant flow data.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Engerix 4D + HBIg Group</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
        </group>
        <group group_id="P2">
          <title>Engerix 3D + HBIg Group</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
        </group>
        <group group_id="P3">
          <title>Engerix 4D</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.</description>
        </group>
        <group group_id="P4">
          <title>Engerix 3D Group</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Year 15</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19">Number of subjects who come back at Year 15 (Month 180) time-point</participants>
                <participants group_id="P2" count="19">Number of subjects who come back at Year 15 (Month 180) time-point</participants>
                <participants group_id="P3" count="14">Number of subjects who come back at Year 15 (Month 180) time-point</participants>
                <participants group_id="P4" count="21">Number of subjects who come back at Year 15 (Month 180) time-point</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Year 16</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17">Number of subjects who come back at Year 16 (Month 192) time-point</participants>
                <participants group_id="P2" count="19">Number of subjects who come back at Year 16 (Month 192) time-point</participants>
                <participants group_id="P3" count="16">Number of subjects who come back at Year 16 (Month 192) time-point</participants>
                <participants group_id="P4" count="22">Number of subjects who come back at Year 16 (Month 192) time-point</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Year 17</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19">Number of subjects who come back at Year 17 (Month 204) time-point</participants>
                <participants group_id="P2" count="17">Number of subjects who come back at Year 17 (Month 204) time-point</participants>
                <participants group_id="P3" count="13">Number of subjects who come back at Year 17 (Month 204) time-point</participants>
                <participants group_id="P4" count="20">Number of subjects who come back at Year 17 (Month 204) time-point</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Year 18</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16">Number of subjects who come back at Year 18 (Month 216) time-point</participants>
                <participants group_id="P2" count="17">Number of subjects who come back at Year 18 (Month 216) time-point</participants>
                <participants group_id="P3" count="14">Number of subjects who come back at Year 18 (Month 216) time-point</participants>
                <participants group_id="P4" count="20">Number of subjects who come back at Year 18 (Month 216) time-point</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Year 19</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17">Number of subjects who come back at Year 19 (Month 228) time-point</participants>
                <participants group_id="P2" count="16">Number of subjects who come back at Year 19 (Month 228) time-point</participants>
                <participants group_id="P3" count="12">Number of subjects who come back at Year 19 (Month 228) time-point</participants>
                <participants group_id="P4" count="18">Number of subjects who come back at Year 19 (Month 228) time-point</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Year 20</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19">Number of subjects who come back at Year 20 (Month 240) time-point</participants>
                <participants group_id="P2" count="17">Number of subjects who come back at Year 20 (Month 240) time-point</participants>
                <participants group_id="P3" count="13">Number of subjects who come back at Year 20 (Month 240) time-point</participants>
                <participants group_id="P4" count="20">Number of subjects who come back at Year 20 (Month 240) time-point</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Engerix 4D + HBIg Group</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
        </group>
        <group group_id="B2">
          <title>Engerix 3D + HBIg Group</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
        </group>
        <group group_id="B3">
          <title>Engerix 4D</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.</description>
        </group>
        <group group_id="B4">
          <title>Engerix 3D Group</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="21"/>
            <count group_id="B5" value="73"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Data are given for the Year 15 time point.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.5" spread="0.51"/>
                    <measurement group_id="B2" value="14.7" spread="0.45"/>
                    <measurement group_id="B3" value="14.6" spread="0.50"/>
                    <measurement group_id="B4" value="14.5" spread="0.51"/>
                    <measurement group_id="B5" value="14.6" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration as Measured by Enzyme-Linked Immunosorbent Assay (ELISA).</title>
        <description>Concentrations given as GMC expressed as milli-international unit per millilitre (mIU/mL).
Note: At Year 15 and 16, a commercial ELISA was used. From Year 17 to Year 20, anti-HBs antibody concentrations were tested with a validated in-house assay with cut-off 3.3mIU/mL.</description>
        <time_frame>At Years 15, 16, 17, 18, 19 and 20</time_frame>
        <population>Analysis was performed on subjects from the Long Term According-to-Protocol (LT ATP) cohort for immunogenicity on subjects with available data at the specified time-points</population>
        <group_list>
          <group group_id="O1">
            <title>Engerix 4D + HBIg Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
          </group>
          <group group_id="O2">
            <title>Engerix 3D + HBIg Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
          </group>
          <group group_id="O3">
            <title>Engerix 4D</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.</description>
          </group>
          <group group_id="O4">
            <title>Engerix 3D Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration as Measured by Enzyme-Linked Immunosorbent Assay (ELISA).</title>
          <description>Concentrations given as GMC expressed as milli-international unit per millilitre (mIU/mL).
Note: At Year 15 and 16, a commercial ELISA was used. From Year 17 to Year 20, anti-HBs antibody concentrations were tested with a validated in-house assay with cut-off 3.3mIU/mL.</description>
          <population>Analysis was performed on subjects from the Long Term According-to-Protocol (LT ATP) cohort for immunogenicity on subjects with available data at the specified time-points</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 15 (N=17;15;12;17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.6" lower_limit="53.4" upper_limit="263.1"/>
                    <measurement group_id="O2" value="14.8" lower_limit="6.8" upper_limit="32.0"/>
                    <measurement group_id="O3" value="142.8" lower_limit="30.4" upper_limit="669.4"/>
                    <measurement group_id="O4" value="24.2" lower_limit="10.0" upper_limit="58.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 16 (N=15;13;12;16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.3" lower_limit="50.0" upper_limit="284.7"/>
                    <measurement group_id="O2" value="14.1" lower_limit="6.8" upper_limit="29.4"/>
                    <measurement group_id="O3" value="134.3" lower_limit="30.1" upper_limit="599.8"/>
                    <measurement group_id="O4" value="22.9" lower_limit="9.7" upper_limit="54.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 17 (N=17;13;11;13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.0" lower_limit="67.2" upper_limit="291.9"/>
                    <measurement group_id="O2" value="8.2" lower_limit="3.9" upper_limit="17.1"/>
                    <measurement group_id="O3" value="70.2" lower_limit="14.3" upper_limit="344.1"/>
                    <measurement group_id="O4" value="17.0" lower_limit="6.7" upper_limit="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 18 (N=14;14;10;13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.3" lower_limit="32.1" upper_limit="211.3"/>
                    <measurement group_id="O2" value="10.8" lower_limit="6.5" upper_limit="17.9"/>
                    <measurement group_id="O3" value="56.5" lower_limit="11.7" upper_limit="271.8"/>
                    <measurement group_id="O4" value="26.1" lower_limit="10.7" upper_limit="63.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 19 (N=13;12;8;11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.3" lower_limit="38.9" upper_limit="274.7"/>
                    <measurement group_id="O2" value="9.5" lower_limit="4.0" upper_limit="22.8"/>
                    <measurement group_id="O3" value="84.9" lower_limit="12.0" upper_limit="600.2"/>
                    <measurement group_id="O4" value="19.9" lower_limit="7.4" upper_limit="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 20 (N=13;13;6;12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" lower_limit="26.6" upper_limit="205.4"/>
                    <measurement group_id="O2" value="14.3" lower_limit="6.7" upper_limit="30.6"/>
                    <measurement group_id="O3" value="297.1" lower_limit="46.0" upper_limit="1919.5"/>
                    <measurement group_id="O4" value="16.3" lower_limit="7.2" upper_limit="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration as Measured by ChemiLuminescence ImmunoAssay (CLIA).</title>
        <description>Concentrations given as GMC expressed as milli-international unit per millilitre (mIU/mL).
Note: There was a change of assay kit at Year 19 time-point, thus for the sake of bridging, blood samples corresponding to Year 19 were re-tested with new CLIA. At Year 19 and 20, anti-HBs antibody concentrations tested with the CLIA with cut-off 6.2 mIU/mL.</description>
        <time_frame>At Years 19 and 20</time_frame>
        <population>Analysis was performed on subjects from the Long Term According-to-Protocol (LT ATP) cohort for immunogenicity on subjects with available data at the specified time-points</population>
        <group_list>
          <group group_id="O1">
            <title>ENGERIX 4D + HBIG GROUP</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
          </group>
          <group group_id="O2">
            <title>ENGERIX 3D + HBIG GROUP</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
          </group>
          <group group_id="O3">
            <title>ENGERIX 4D</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.</description>
          </group>
          <group group_id="O4">
            <title>ENGERIX 3D GROUP</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration as Measured by ChemiLuminescence ImmunoAssay (CLIA).</title>
          <description>Concentrations given as GMC expressed as milli-international unit per millilitre (mIU/mL).
Note: There was a change of assay kit at Year 19 time-point, thus for the sake of bridging, blood samples corresponding to Year 19 were re-tested with new CLIA. At Year 19 and 20, anti-HBs antibody concentrations tested with the CLIA with cut-off 6.2 mIU/mL.</description>
          <population>Analysis was performed on subjects from the Long Term According-to-Protocol (LT ATP) cohort for immunogenicity on subjects with available data at the specified time-points</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>YEAR 19 (N=14;12;6;11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.1" lower_limit="26.7" upper_limit="135.5"/>
                    <measurement group_id="O2" value="5.8" lower_limit="3.3" upper_limit="10.0"/>
                    <measurement group_id="O3" value="159.0" lower_limit="32.6" upper_limit="776.5"/>
                    <measurement group_id="O4" value="11.7" lower_limit="5.0" upper_limit="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>YEAR 20 (N=16;13;7;13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0" lower_limit="18.3" upper_limit="105.9"/>
                    <measurement group_id="O2" value="5.1" lower_limit="3.1" upper_limit="8.6"/>
                    <measurement group_id="O3" value="83.5" lower_limit="16.2" upper_limit="431.7"/>
                    <measurement group_id="O4" value="9.5" lower_limit="4.3" upper_limit="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above Pre-defined Cut-off Values Enzyme-Linked Immunosorbent Assay (ELISA).</title>
        <description>Anti-hepatitis B surface antigen (anti-HBs) antibody cut-off values assessed include 1.0 and 10 mIU/mL.</description>
        <time_frame>At Years 15, 16, 17, 18, 19 and 20</time_frame>
        <population>Analysis was performed on subjects from the Long Term According-to-Protocol (LT ATP) cohort for immunogenicity on subjects with available data at the specified time-points</population>
        <group_list>
          <group group_id="O1">
            <title>Engerix 4D + HBIg Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
          </group>
          <group group_id="O2">
            <title>Engerix 3D + HBIg Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
          </group>
          <group group_id="O3">
            <title>Engerix 4D</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.</description>
          </group>
          <group group_id="O4">
            <title>Engerix 3D Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above Pre-defined Cut-off Values Enzyme-Linked Immunosorbent Assay (ELISA).</title>
          <description>Anti-hepatitis B surface antigen (anti-HBs) antibody cut-off values assessed include 1.0 and 10 mIU/mL.</description>
          <population>Analysis was performed on subjects from the Long Term According-to-Protocol (LT ATP) cohort for immunogenicity on subjects with available data at the specified time-points</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 15 (≥ 1.0 mIU/mL) (N=17;15;12;17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 15 (≥ 10 mIU/mL) (N=17;15;12;17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 16 (≥ 1.0 mIU/mL) (N=15;13;12;16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 16 (≥ 10 mIU/mL) (N=15;13;12;16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 17 (≥ 1.0 mIU/mL) (N=17;13;11;13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 17 (≥ 10 mIU/mL) (N=17;13;11;13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 18 (≥ 1.0 mIU/mL) (N=14;14;10;13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 18 (≥ 10 mIU/mL) (N=14;14;10;13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 19 (≥ 1.0 mIU/mL) (N=14;12;8;11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 19 (≥ 10 mIU/mL) (N=14;12;8;11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 20 (≥ 1.0 mIU/mL) (N=13;13;6;12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 20 (≥ 10 mIU/mL) (N=13;13;6;12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above Pre-defined Cut-off Values as Measured by ChemiLuminescence ImmunoAssay (CLIA)</title>
        <description>Anti-hepatitis B surface antigen (anti-HBs) antibody cut-off values assessed include 1.0 and 10 mIU/mL.
Note: Missing CLIA anti-HBs concentrations, for subjects with ELISA results available, are estimated by multiple imputations and GMCs and number of subjects were adjusted for these imputations.</description>
        <time_frame>At Years 19 and 20</time_frame>
        <population>Analysis was performed on subjects from the Long Term According-to-Protocol (LT ATP) cohort for immunogenicity on subjects with available data at the specified time-points</population>
        <group_list>
          <group group_id="O1">
            <title>ENGERIX 4D + HBIG GROUP</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
          </group>
          <group group_id="O2">
            <title>ENGERIX 3D + HBIG GROUP</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
          </group>
          <group group_id="O3">
            <title>ENGERIX 4D</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.</description>
          </group>
          <group group_id="O4">
            <title>ENGERIX 3D GROUP</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above Pre-defined Cut-off Values as Measured by ChemiLuminescence ImmunoAssay (CLIA)</title>
          <description>Anti-hepatitis B surface antigen (anti-HBs) antibody cut-off values assessed include 1.0 and 10 mIU/mL.
Note: Missing CLIA anti-HBs concentrations, for subjects with ELISA results available, are estimated by multiple imputations and GMCs and number of subjects were adjusted for these imputations.</description>
          <population>Analysis was performed on subjects from the Long Term According-to-Protocol (LT ATP) cohort for immunogenicity on subjects with available data at the specified time-points</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 19 (≥ 1.0 mIU/mL) (N=14;12;6;11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0"/>
                    <measurement group_id="O2" value="4.2"/>
                    <measurement group_id="O3" value="6.0"/>
                    <measurement group_id="O4" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 19 (≥ 10 mIU/mL) (N=14;12;6;11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0"/>
                    <measurement group_id="O2" value="3.9"/>
                    <measurement group_id="O3" value="5.0"/>
                    <measurement group_id="O4" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 20 (≥ 1.0 mIU/mL) (N=16;13;7;13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1"/>
                    <measurement group_id="O2" value="5.4"/>
                    <measurement group_id="O3" value="6.0"/>
                    <measurement group_id="O4" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 20 (≥ 10 mIU/mL) (N=16;13;7;13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2"/>
                    <measurement group_id="O2" value="2.1"/>
                    <measurement group_id="O3" value="5.0"/>
                    <measurement group_id="O4" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Positive Results for Serological Markers for Hepatitis B Infection</title>
        <description>Serological markers for hepatitis B infection assessed are hepatitis B surface antigen (HBsAg), antibodies to hepatitis B core antigen (anti-HBc), hepatitis B e antigen (HBeAg) and antibodies to hepatitis B e antigen (anti-HBe).</description>
        <time_frame>At Years 15, 16, 17, 18, 19 and 20</time_frame>
        <population>Analysis was performed on the Long Term Total Cohort (LT total cohort) on subjects with available data for the specified marker.</population>
        <group_list>
          <group group_id="O1">
            <title>Engerix 4D + HBIg Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
          </group>
          <group group_id="O2">
            <title>Engerix 3D + HBIg Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
          </group>
          <group group_id="O3">
            <title>Engerix 4D</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.</description>
          </group>
          <group group_id="O4">
            <title>Engerix 3D Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Positive Results for Serological Markers for Hepatitis B Infection</title>
          <description>Serological markers for hepatitis B infection assessed are hepatitis B surface antigen (HBsAg), antibodies to hepatitis B core antigen (anti-HBc), hepatitis B e antigen (HBeAg) and antibodies to hepatitis B e antigen (anti-HBe).</description>
          <population>Analysis was performed on the Long Term Total Cohort (LT total cohort) on subjects with available data for the specified marker.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 15 HBsAg (N=19;19;14;21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 15 Anti-HBc (N=19;19;14;21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 15 HBeAg (N=4;7;1;8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 15 Anti-HBe (N=4;7;1;8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 16 HBsAg (N=16;17;16;22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 16 Anti-HBc (N=16;17;16;22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 16 HBeAg (N=6;5;3;11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 16 Anti-HBe (N=6;5;3;11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 17 HBsAg (N=19;17;13;19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 17 Anti-HBc (N=19;17;13;20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 17 HBeAg (N=9;5;4;10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 17 Anti-HBe (N=9;5;4;10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 18 HBsAg (N=16;17;14;20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 18 Anti-HBc (N=16;17;14;20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 18 HBeAg (N=8;7;4;10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 18 Anti-HBe (N=8;7;4;10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 19 HBsAg (N=17;16;12;18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 19 Anti-HBc (N=17;16;12;18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 19 HBeAg (N=8;7;5;10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 19 Anti-HBe (N=8;7;5;10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 20 HBsAg (N=19;17;12;20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 20 Anti-HBc (N=19;17;12;20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 20 HBeAg (N=8;7;6;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 20 Anti-HBe (N=10;9;6;15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Different Hepatitis B Infection Statuses</title>
        <description>Categories hepatitis B (HB) infection:
Chronic infection: HBsAg and anti-HBc pos (pos) in more than two consecutive samples
False positive: single HB marker (HBsAg, HBeAg, anti-HBc) pos + all other markers negative (neg) in one sample. Consecutive time points all neg.
Possible subclinical breakthrough infection: One or more HB markers pos in one or more consecutive samples.
Isolated natural booster: &gt;4-fold increase of anti-HBs concentrations if &lt;100 mIU/mL at previous sample OR &gt;2- fold increase of anti-HBs concentrations if &gt;=100 mIU/mL at previous sample + other markers neg</description>
        <time_frame>Over the entire follow up period (Final assessment of clinical significance was analyzed after the Year 20 time point)</time_frame>
        <population>Analysis was performed on the Long Term Total Cohort (LT total cohort). The maximum amount of subjects who have participated in any of the time points in this study has been given as number of participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Engerix 4D + HBIg Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
          </group>
          <group group_id="O2">
            <title>Engerix 3D + HBIg Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
          </group>
          <group group_id="O3">
            <title>Engerix 4D</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.</description>
          </group>
          <group group_id="O4">
            <title>Engerix 3D Group</title>
            <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Different Hepatitis B Infection Statuses</title>
          <description>Categories hepatitis B (HB) infection:
Chronic infection: HBsAg and anti-HBc pos (pos) in more than two consecutive samples
False positive: single HB marker (HBsAg, HBeAg, anti-HBc) pos + all other markers negative (neg) in one sample. Consecutive time points all neg.
Possible subclinical breakthrough infection: One or more HB markers pos in one or more consecutive samples.
Isolated natural booster: &gt;4-fold increase of anti-HBs concentrations if &lt;100 mIU/mL at previous sample OR &gt;2- fold increase of anti-HBs concentrations if &gt;=100 mIU/mL at previous sample + other markers neg</description>
          <population>Analysis was performed on the Long Term Total Cohort (LT total cohort). The maximum amount of subjects who have participated in any of the time points in this study has been given as number of participants analyzed.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chronic HB infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>False positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possible subclinical breakthrough HB infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Isolated natural booster</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>As no adverse events data were collected during this study the number of participants at risk is 0 for all groups.</desc>
      <group_list>
        <group group_id="E1">
          <title>Engerix 4D + HBIg Group</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
        </group>
        <group group_id="E2">
          <title>Engerix 3D + HBIg Group</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.</description>
        </group>
        <group group_id="E3">
          <title>Engerix 4D</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.</description>
        </group>
        <group group_id="E4">
          <title>Engerix 3D Group</title>
          <description>Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). Additional tables have been generated following partial retesting and reanalysis of the results at Years 19 and 20.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

